Subcortical vascular dementia (VaD) is characterized by executive dysfunction and behavioral problems, reflecting deterioration of the frontal lobe. This study aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the typical symptoms of subcortical VaD. Patients receiving rivastigmine showed a slight improvement in executive functions and in behavior. Side effects in both groups were tolerable and there were no study withdrawals. Moreover, there are no drug interactions with other therapies previously and concomitantly assumed. Improvements in domains that characterize subcortical VaD were observed, indicating that rivastigmine may have provided targeted treatment in areas of the brain that are particularly affected in this patient population.
Román GC, Tatemichi TK, Erkinjuntti T, et al.: Vascular dementia: Diagnostic criteria for research studies. Report of the NINDSAIREN International Workshop. Neurology. 1993; 43(2): 250-260.
2.
Wetterling T, Kanitz RD, Borgis KJ: The ICD-10 criteria for vascular dementia. Dementia. 1994; 5(3-4): 185-188.
3.
Erkinjuntti T: Vascular dementia: Challenge of clinical diagnosis. Int Psychogeriatr.1997; 9(Suppl 1): 77-83.
4.
Pantoni L, Rossi R, Inzitari D, et al.: Efficacy and safety of nimodipine in subcortical vascular dementia: A subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci.2000; 175(2): 124-134.
5.
Chui H: Dementia associated with subcortical ischemic vascular disease. Philadelphia: American Academy, 2001; 2FC.005-89-107.
6.
Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol. 1993; 50(8): 873-880.
7.
McPherson SE, Cummings JL: Neurospychological aspects of vascular dementia. Brain Cogn. 1996; 31(2): 269-282.
8.
Looi JC, Sachdev PS: Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999; 53(4): 670-678.
9.
Saito H, Togashi H, Yoshioka M, et al.: Animal models of vascular dementia with emphasis on stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol Suppl.1995; 22(1): S257-259.
10.
Togashi H, Matsumoto M, Yoshioka M, et al.: Neurochemical profiles in cerebrospinal fluid of stroke-prone spontaneously hypertensive rats. Neurosci Lett.1994; 166(1): 117-120.
11.
Kimura S, Saito H, Minami M, et al.: Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology. 2000; 153(1-3): 167-178.
12.
Togashi H, Kimura S, Matsumoto M, et al.: Cholinergic changes in the hippocampus of stroke-prone spontaneously hypertensive rats. Stroke. 1996; 27(3): 520-526.
13.
Scremin OU, Li MG, Scremin AM, et al.: Cholinesterase inhibition improves blood flow in the ischemic cerebral cortex. Brain Res Bull. 1997; 42(1): 59-70.
14.
Gottfries CG, Blennow K, Karlsson I, et al.: The neurochemistry of vascular dementia. Dementia. 1994; 5(3-4): 163-167.
15.
Wallin A, Blennow K, Gottfries CG: Neurochemical abnormalities in vascular dementia. Dementia. 1989; 1: 120-130.
Ballard CG: Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition. Eur Neurol. 2002; 47(1): 64-70.
18.
Erkinjuntti T, Bowler JV, DeCarli C, et al.: Imaging of static brain lesions in vascular dementia: Implications for clinical trials. Alzheimers Dis Assoc Disord. 1999; 13(Suppl 3): S81-S90.
19.
Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140: 566-572.
20.
Folstein MF, Folstein SE, McHugh PR: “Mini-Mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12(3): 189-198.
21.
Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987; 48(8): 314-318.
22.
Manos PJ: The utility of the ten-point clock test as a screen for cognitive impairment in general hospital patients. Gen Hosp Psychiatry. 1997; 19(6): 439-444.
Reisberg B, Borenstein J, Salob SP, et al.: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry. 1987; 48 Suppl.: 9-15.
25.
Yesavage JA, Brink TL, Rose TL, et al.: Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res.1982-83; 17(1): 37-49.
26.
Conwell Y, Forbes NT, Cox C, et al.: Validation of a measure of physical illness burden at autopsy: The Cumulative Illness Rating Scale. J Am Geriatr Soc.1993; 41(1): 38-41.
27.
European Pentoxifylline Multi-Infarct Dementia (EPMID) Study Group: European pentoxifylline multi-infarct dementia. Eur Neurol. 1996; 36(5): 315-321.
28.
Marcusson J, Rother M, Kittner B, et al.: A 12-month, randomised, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. Dement Geriatr Cogn Disord.1997; 8(5): 320-328.
29.
Sachdev PS, Brodaty H, Looi JC: Vascular dementia: Diagnosis, management and possible prevention. Med J Aust. 1999; 170(2): 81-85.
30.
Erkinjuntti T, Lilienfeld S: Galantamine shows efficacy in patients with Alzheimer's disease with cerebrovascular disease or probable vascular dementia. Poster presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia, PA, USA, May 2001.
31.
Erkinjuntti T, Kurz A, Gauthier S, et al.: Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomised trial. Lancet. 2002; 359(9314): 1283-1290.
32.
Kumar V, Anand R, Messina J, et al.: An efficacy and safety analysis of Exelon in Alzheimer's disease with concurrent vascular risk factors. Eur J Neurol.2000; 7(2): 159-169.
33.
Moretti R, Torre P, Antonello RM, et al.: Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow up. Eur J Neurol.2001; 8(4): 361-362.
34.
Moretti R, Torre P, Antonello RM, et al.: Rivastigmine in subcortical vascular dementia: An open 22-month study. J Neurol Sci.2002; 203-204: 141-146.
35.
Moretti R, Torre P, Antonello RM, et al.: An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specific to patients with subcortical vascular dementia. Curr Ther Res.2002; 63: 443-458.
36.
Moretti R, Torre P, Antonello RM, et al.: Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: An open, 16-month, comparative study. J Neurol Sci.2003, submitted.
37.
Vennerica A, Shanks MF, Staff RT, et al.: Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport. 2002; 13(1): 83-87.
38.
Sharma T, Kumari V, Mitterschiffthaler M, et al.: Cognitive effects of rivastigmine in Alzheimer's disease: An fMRI study. Poster presented at the American College of Neuropsychopharmacology 40th Annual Meeting, Waikoloa, Hawaii, December 9-13, 2001.
39.
Adler G, Brassen S: Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients. Neuropsychobiology. 2001; 43(4): 273-276.
40.
Nordberg A, Stefanova E, Almkvist O, et al.: Improved cortical glucose metabolism in Alzheimer's disease (AD) patients treated with rivastigmine for 1 year. J Neurol Sci.2001; 187(Suppl 1): P0142-P0142.
41.
Almkvist O, Darreh-Shori T, Spiegel R, et al.: Improved cognition and plasma cholinesterase (ChE) inhibition in AD patients receiving rivastigmine for 1 year: Differential effects across time. J Neurol Sci. 2001; 187(Suppl 1): P0143-P0143.
42.
Nordberg A, Darreh-Shori T, Svensson A, et al.: Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in CSF of mild AD patients following 12 months of rivastigmine treatment. J Neurol Sci.2001; 187(Suppl 1): P0144-P0144.
43.
McKeith I, Del Ser T, Spano PF, et al.: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebocontrolled international study. Lancet. 2000; 356(9247): 2031-2036.
44.
Harding AJ, Broe GA, Halliday GM: Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002; 125(Pt 2): 391-403.
45.
Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian hallucinosis. Proc Assoc Br Neurologists. 2001; 67: (Abstract).
46.
Polinsky RJ: Clinical pharmacology of rivastigmine: A newgeneration acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther. 1998; 20(4): 634-647.
47.
Grossberg GT, Stahelin HB, Messina JC, et al.: Lack of adverse pharmacodynamic drug interactions with rivastigmine and twentytwo classes of medications. Int J Geriatr Psychiatry. 2000; 15(3): 242-247.
